Tag: cannabis
-
![Heritage Cannabis (CANN.C) rides a sweet October open to a near double, and continues to expand]()
Heritage Cannabis (CANN.C) rides a sweet October open to a near double, and continues to expand
A widening distribution net with award winning products and it shouldn’t come as much of a surprise that Heritage Cannabis (CANN.C) has had an excellent October so far and shows no signs of slowing down. They’ve widened their distribution and availability chain a little more in the past week, adding their wares with Patient Choice,…
-
Watch me: I can sell you on CLS Holdings (CLSH.C), with its one dispensary, being a better buy than Trulieve (TRUL.C), with 52
Let’s take a step back. Take a breath. Maybe meditate or toss back a tequila shot. Okay, we good for a chat? It’s been a rough few years for the cannabis crowd, and a rough last year for everyone else. With Aurora Cannabis (ACB.T) losing the gross national product of Panama, Chuck Rifici bailing from…
-
Heritage Cannabis (CANN.C) is so close profitability, it’s breaking social distancing rules
Sharples believes that Purefarma, Pura Vida, new contract manufacturing agreements, expansion of Canadian territories, the edibles product launch and the acquisition of Opticann expanding CANN’s U.S. presence will accelerate revenue going forward.
-
Revive (RVV.C) gives update on FDA Phase 3 clinical trial
Given the grim human and financial data, it’s no surprise that biotech companies and their shareholders are focused on developing coronavirus solutions.
-
![Xphyto (XPHY.C) advances its Oral Dissolvable Film (ODF) technology for CBD and THC medical markets]()
Xphyto (XPHY.C) advances its Oral Dissolvable Film (ODF) technology for CBD and THC medical markets
Increased product efficacy and patient convenience is anticipated through faster onset of drug action, more predictable therapeutic activity and ease of use.
-
![Xphyto (XPHY.C) updates shareholders on rapid COVID-19 (SARS-CoV-2) screening test]()
Xphyto (XPHY.C) updates shareholders on rapid COVID-19 (SARS-CoV-2) screening test
Xphyto and 3a are developing rapid screening tests for COVID-19 and other high-risk pandemic threats, including H1N1 (swine flu) and H5N1 (avian flu), with a specific focus on early pre-symptomatic and asymptomatic stages of infection
-
Revive’s (RVV.C) Bucillamine Covid-19 treatment advances through development pipeline
Given the grim human and financial data, it’s no surprise that biotech companies and their shareholders are focussed on developing coronavirus solutions.
-
Heritage Cannabis (CANN.C) to develop vape oil with Sugarbud’s biomass
Heritage is positioning itself to radically expand its sales territory.
-
Revive (RVV.C) advances drug delivery tech for psychedelics
Revive has a partnership agreement with the Reed Research Group out of the University of Wisconsin-Madison to evaluate novel formulations of psilocybin.
-
Heritage Cannabis (CANN.C) acquires Opticann – to create an international medical footprint
Sharples’ plan is to leverage Opticann’s international relationships to build “an international medical product sales footprint”.
